Legend Biotech Corporation (NASDAQ: LEGN) announced the appointment of Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, following a board-led search process.

Zhang succeeds Alan Bash, who had served as Interim CEO since July 2026 and will return to his role as President of CARVYKTI, the company's cell therapy treatment for relapsed or refractory multiple myeloma, developed in partnership with Johnson & Johnson.

Zhang most recently served as Chief Commercial Officer for Novartis International, where she also led the company's China business and innovative medicines organization. Earlier in her career, she held leadership positions at AstraZeneca, Pfizer, and McKinsey & Company.

"It is a privilege to join Legend Biotech at an important moment in the Company's growth," Zhang said. "I look forward to working with the talented team at Legend to build on this strong foundation, advance our pipeline, expand our impact, and execute on our long-term growth strategy."

Frank Zhang, Chairman of the Board, said the board concluded that Ingrid Zhang is "the right leader to guide Legend Biotech through its next phase of growth," citing her operational and strategic experience leading global businesses.

Legend Biotech is headquartered in Bridgewater, N.J., and employs more than 3,000 people.